Improving Care for Women With Urinary Incontinence (EMPOWER)
- Conditions
- Urinary Incontinence
- Interventions
- Other: Patient EducationOther: Nurse NavigationOther: ChatBot
- Registration Number
- NCT05515198
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Brief Summary
The overall goal is to improve diagnosis and non-operative management of urinary incontinence in women.
- Detailed Description
In the study, patients will be screened in primary care offices for symptoms of urinary incontinence. Women with positive screening results will be asked if they are interested in participating in an implementation study where women will be assigned to one of the three following groups:
1. Usual Care plus Patient Educational Opportunities - The patient's urinary incontinence will be managed using standard of care treatment by the patient's primary care provider. Patients will be offered educational opportunities about urinary incontinence.
2. Nurse Navigation - Along with the treatment described for "Usual Care plus Patient Educational Opportunities," a nurse navigator will work with the patient to implement behavioral changes and provide education and physical therapy options. In addition, the navigator will be available to answer the patient's questions in a timely fashion and help the patient move through the care pathway.
3. Nurse Navigation and ChatBot - Along with the treatment described for "Usual Care plus Patient Educational Opportunities" and "Nurse Navigation," this group will include a ChatBot feature which will allow a patient to directly and privately communicate with an artificial intelligence-driven ChatBot, also known as a "conversational agent," that will provide education and help the patient navigate the care pathway.
All participants will complete questionnaires throughout their enrollment and data will be collected from medical records. The study team will analyze the data at six months after the original appointment/study enrollment, assess adherence to therapy and how the therapy impacted the outcomes the team hopes to improve, such as improvement in symptoms. The study will be implemented over three subsequent time periods called Wave 1, Wave 2 and Wave 3 with primary care practices from two geographic regions being involved in each wave (6 regions total). Participants in Wave 1 will be followed for a total of 18 months, while participants in Wave 2 will be followed for a total of 12 months, and participants in Wave 3 will be followed for 6 months. Primary care providers at all participating practices will be offered educational opportunities related to urinary incontinence.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 400
- Female patient having a primary care provider visit at University Hospitals (UH) Cleveland Primary Care Institute (PCI)
- ≥ 18 years old
- Scores 1 or higher on the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-SF)
None
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 2 Patient Education Patient Education + Nurse Navigation Arm 2 Nurse Navigation Patient Education + Nurse Navigation Arm 3 Nurse Navigation Patient Education + Nurse Navigation + ChatBot Arm 3 ChatBot Patient Education + Nurse Navigation + ChatBot Arm 1 Patient Education Patient Education Arm 3 Patient Education Patient Education + Nurse Navigation + ChatBot
- Primary Outcome Measures
Name Time Method Patients' UI symptoms as measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) 18 months (Wave 1) The International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) assess frequency, severity and impact on quality of life (QoL) of patients' urinary incontinence symptoms. The result of the ICIQ-UI SF is a composite score ranging from 0 to 21, with higher scores indicating more severe incontinence.
Change in patients' UI symptoms as measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) Baseline and Months 2 and 6 (all Waves) The International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) assess frequency, severity and impact on quality of life (QoL) of patients' urinary incontinence symptoms. The result of the ICIQ-UI SF is a composite score ranging from 0 to 21, with higher scores indicating more severe incontinence.
- Secondary Outcome Measures
Name Time Method Impact of UI on patients' quality of life as measured by the ICIQ-LUTSqol 18 months (Wave 1) The impact of urinary incontinence on quality of life will be assessed by the Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol). The ICIQ-LUTSqol total score ranges from 19 to 76, with higher scores indicating increased impact on quality of life.
Number of practices that implement a UI point person as measured by the practice survey 1 month post completion of each Wave's enrollment period Implementation of a UI point person will be measured as a percentage of sites answer yes on practice survey.
Urinary symptoms as measured by the UDI-6 18 months (Wave 1) How bothersome a patient's urinary symptoms are will be assessed by the Urinary Distress Inventory (UDI-6). The UDI-6 total score ranges from 0 to 100, with higher scores indicating more bothersome symptoms.
Patients' perceived self-efficacy for UI communication as measured by the PEPPI 18 months (Wave 1) Patients' perceived confidence in their ability to communicate their health concerns around UI will be assessed by the Patient- Perceived Self-Efficacy in Patient-Physician Interactions (PEPPI) Questionnaire modified for UI. The PEPPI total score ranges from 0 to 50, with higher scores indicating greater self-efficacy.
Change in patient empowerment as measured by a patient survey Baseline and Months 2 and 6 (all Waves) Patient empowerment will be measured by a patient survey to measure with percentage of patients answering yes to speaking with their provider about UI.
Change in overactive bladder symptom severity as measured by the OABSS Baseline and Months 2 and 6 (all Waves) Patients' overactive bladder symptom severity will be assessed by the Overactive Bladder Symptom Score (OABSS). The OABSS total score ranges from 0 to 15, with higher scores indicating more severe symptoms.
Change in urinary symptoms as measured by the UDI-6 Baseline and Months 2 and 6 (all Waves) How bothersome a patient's urinary symptoms are will be assessed by the Urinary Distress Inventory (UDI-6). The UDI-6 total score ranges from 0 to 100, with higher scores indicating more bothersome symptoms.
Change in impact of UI on patients' quality of life as measured by the ICIQ-LUTSqol Baseline and Months 2 and 6 (all Waves) The impact of urinary incontinence on quality of life will be assessed by the Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol). The ICIQ-LUTSqol total score ranges from 19 to 76, with higher scores indicating increased impact on quality of life.
Patients' perceived symptom improvement as measured by the PGI-I 18 months (Wave 1) Patients' perceived improvement in UI symptoms will be assessed with the Patient Global Impression of Improvement (PGI-I). PGI-I measures improvement on a scale of 1 "very much better" to 7 "very much worse."
Change in patients' perceived self-efficacy for UI communication as measured by the PEPPI Baseline and Months 2 and 6 (all Waves) Patients' perceived confidence in their ability to communicate their health concerns around UI will be assessed by the Patient-Perceived Self-Efficacy in Patient-Physician Interactions (PEPPI) Questionnaire modified for UI. The PEPPI total score ranges from 0 to 50, with higher scores indicating greater self-efficacy.
Overactive bladder symptom severity as measured by the OABSS 18 months (Wave 1) Overactive bladder symptom severity will be assessed by the Overactive Bladder Symptom Score (OABSS). The OABSS total score ranges from 0 to 15, with higher scores indicating more severe symptoms.
Change in patients' perceived symptom improvement as measured by the PGI-I Months 2 and 6 (all Waves) Patients' perceived improvement in UI symptoms will be assessed with the Patient Global Impression of Improvement (PGI-I). PGI-I measures improvement on a scale of 1 "very much better" to 7 "very much worse."
Number of practices that maintain a UI management intervention as measured by the practice survey 1 month post completion of each Wave's enrollment period Maintenance of UI management intervention will be assessed by practice survey with indication of continuation for each intervention component.
Trial Locations
- Locations (1)
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States